Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03525613 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
A Phase 3 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 637
- Enrollment target
NCT03525613 is a Phase 3 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 637 participants.
The verdict
NCT03525613, a Phase 3 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 637 participants
- Enrollment target
Study Summary
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
Interventions
- OTHER Sham Procedure
- DRUG APL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2018-08-31 |
| Est. Completion | 2022-06-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03525613
The ClinicalTrials.gov registry entry for NCT03525613 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 637 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Procedure is the first listed.
NCT03525613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03525613 about?
NCT03525613 is a clinical study titled "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration". This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
What is the current status of trial NCT03525613?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 637 participants. The study started on 2018-08-31. Estimated completion is 2022-06-28.
What interventions are being tested in trial NCT03525613?
The interventions under investigation include: Sham Procedure (OTHER), APL-2 (DRUG).
Who is sponsoring clinical trial NCT03525613?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.